We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Pharmacotoxicology of Trichloroethylene Metabolites

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: May 21, 2010
Last Update Posted: May 7, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Institutes of Health (NIH)
Information provided by (Responsible Party):
University of Florida
Results First Submitted: November 20, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: None (Open Label);   Primary Purpose: Basic Science
Condition: Healthy
Interventions: Drug: Dichloroacetate environmental dose
Drug: Chloral Hydrate environmental dose
Drug: Dichloroacetate therapeutic dose
Drug: Chloral Hydrate therapeutic dose

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited using an ad approved by the Institutional Review Board (IRB) and by undergoing a screening exam to determine eligibility.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
There were 27 total participants, with 4 eligible sessions (periods) for each, with the order to be randomized. As per CT.Gov instructions, the periods are identified by treatment rather than order.There were no planned comparisons between the arms of this pharmacological study. Withdrawals entered but did not reach baseline.

Reporting Groups
All Subjects The intent was to have all subjects participate in all four sessions (periods). These were environmental chloral hydrate +/- environmental DCA and therapeutic chloral hydrate +/- therapeutic DCA. Patient participation: 4 Sessions (N=2), 3 Sessions (N=1), 2 Sessions (N=6), 1 Session (N=8), 0 Sessions (N=10), Total: N=27 patients participated in 31 sessions.

Participant Flow for 4 periods

Period 1:   Environment Chloral Hydrate and DCA (1A)
    All Subjects

Period 2:   Environmental Chloral Hydrate (1B)
    All Subjects
STARTED   8 [1] 
[1] Per the suggestion from Heather, periods are not in chronological order, but defined by treatment.

Period 3:   Therapeutic Chloral Hydrate and DCA (2A)
    All Subjects

Period 4:   Therapeutic Chloral Hydrate (2B)
    All Subjects

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Withdrawals before their treatment was to begin, as all were scheduled to participate in all 4 participate.

Reporting Groups
All Subjects Intent was to have all subjects participate in all sessions (periods)

Baseline Measures
   All Subjects 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   27 
>=65 years   0 
[Units: Years]
Mean (Standard Deviation)
 28.0  (7.9) 
[Units: Participants]
Female   15 
Male   12 
Region of Enrollment 
[Units: Participants]
United States   27 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A.   [ Time Frame: 6 Days ]

2.  Primary:   Difference in Half Lives 5 Day Less One Day Exposure in Trichloroacetate   [ Time Frame: 5 days ]

3.  Primary:   Urinary Maleylacetone Levels After 5 Day Exposure to Therapeutic Chloral Hydrate (Arm 2B)   [ Time Frame: 5 days ]

4.  Secondary:   Detectable DCA After Day 1 in Serum (0=No 1=Yes)   [ Time Frame: 1 day ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Subjects were asked to wait 30 days in between doses of medication. Some of the participants could not wait the entire 4 months to finish the study and thus dropped out before they completed the 4 arms. Ten were enrolled, screened, but did not start

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Peter W. Stacpoole,MD
Organization: University of Florida
phone: (352) 273-9023
e-mail: pws@ufl.edu

Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT01128270     History of Changes
Other Study ID Numbers: IRB#107-10
RO1ESO141617 ( Other Grant/Funding Number: National Institute of Health RO1ESO14167 )
First Submitted: May 20, 2010
First Posted: May 21, 2010
Results First Submitted: November 20, 2013
Results First Posted: May 7, 2014
Last Update Posted: May 7, 2014